Cytokinetics, Inc.
Cytokinetics Announces Issuance of $750 Million Convertible Senior Notes
Summary
On September 19, 2025, Cytokinetics, Incorporated issued $750 million aggregate principal amount of 1.75% Convertible Senior Notes due 2031. The issuance included the full exercise of the initial purchasers' option to purchase up to an additional $100 million in notes. Cytokinetics expects to use the net proceeds from the offering to support the commercial launch of aficamten, continue its development program, advance its research pipeline, and for general corporate purposes. The notes will be convertible into cash, shares of Cytokinetics' common stock, or a combination of both. The notes are senior, unsecured obligations of Cytokinetics and will accrue interest payable semi-annually in arrears.
Profitelligence Alerts
Get alerts for CYTK
Be first to know when Cytokinetics, Inc. files with the SEC.
Filing Categories
Advertisement
About Cytokinetics, Inc.
Cytokinetics, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of novel muscle activators as potential treatments for debilitating diseases. Primarily, the company's work aims to address unmet medical needs in the fields of neurology and cardiology, offering therapeutic solutions that target muscle function. Cytokinetics' research centers on small molecule drugs that modulate muscle performance, which could significantly aid patients suffering from heart failure, amyotrophic lateral sclerosis (ALS), and other muscle-related conditions. The company is actively involved in clinical trials and collaborates with other notable entities in its quest for innovative medical advancements. Its contributions to the healthcare sector exemplify the growing role of targeted therapy in improving patient outcomes. Headquartered in South San Francisco, California, Cytokinetics operates as a key player in the biotechnology landscape, with a commitment to pioneering treatments that leverage the complex mechanisms of muscle biology.
Official SEC Documents
Advertisement